Loading…

A Rare Case of Refractory Nodal Marginal Zone Lymphoma in a Child, Successfully Cured by Allogeneic Stem Cell Transplant: A Case Report

ABSTRACT Background Nodal marginal zone lymphoma (NMZL) is a rare form of non‐Hodgkin lymphoma (NHL), accounting for around 2% of all NHL in pediatrics and adults. It is considered the least common subtype of marginal zone lymphoma, which is rarely seen in pediatrics and is usually viewed as a mild...

Full description

Saved in:
Bibliographic Details
Published in:Pediatric transplantation 2024-09, Vol.28 (6), p.e14835-n/a
Main Authors: Memon, Shahbaz, Almudayfir, Ziyad, Elbashir, Enas, Taher, Leena, Rogi, Fayhan, Essa, Mohammad
Format: Article
Language:English
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:ABSTRACT Background Nodal marginal zone lymphoma (NMZL) is a rare form of non‐Hodgkin lymphoma (NHL), accounting for around 2% of all NHL in pediatrics and adults. It is considered the least common subtype of marginal zone lymphoma, which is rarely seen in pediatrics and is usually viewed as a mild disease. In adults, its presentation varies from mild to aggressive disease with multiple lymph node enlargement and systemic symptoms. Case Report Here, we report an interesting case of a 31‐month‐old boy who developed refractory EBV‐positive NMZL with extensive disease. The tumor did not respond well to conventional chemotherapy and Rituximab. Therefore, we manage the disease with second‐line chemotherapy, including bortezomib, followed by an allogeneic hematopoietic stem cell transplant (HSCT) with an excellent outcome. Conclusion Very few cases have been reported for aggressive NMZL children. The tumor was refractory to first line chemotherapy. However, the successful outcome was achieved by allogeneic stem cell transplant with myeloablative conditioning chemotherapy. The significance of this particular case is that this is the first reported case from pediatrics for refractory NMZL, which responded well to allogeneic stem cell transplant.
ISSN:1397-3142
1399-3046
1399-3046
DOI:10.1111/petr.14835